TY - JOUR T1 - Assessing the risk of COVID-19 epidemic resurgence in relation to the Delta variant and to vaccination passes JF - medRxiv DO - 10.1101/2021.05.07.21256847 SP - 2021.05.07.21256847 AU - Tyll Krueger AU - Krzysztof Gogolewski AU - Marcin Bodych AU - Anna Gambin AU - Giulia Giordano AU - Sarah Cuschieri AU - Thomas Czypionka AU - Matjaz Perc AU - Elena Petelos AU - Magdalena RosiƄska AU - Ewa Szczurek Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/18/2021.05.07.21256847.abstract N2 - The introduction of COVID-19 vaccination passes (VPs) by many countries coincides with the Delta variant fast becoming dominant across Europe. A thorough assessment of their impact on epidemic dynamics is still lacking. Here, we propose the VAP-SIRS model that considers possibly lower restrictions for the VP holders than for the rest of the population, imperfect vaccination effectiveness against infection, rates of (re-)vaccination and waning immunity, fraction of never-vaccinated, and the increased transmissibility of the Delta variant. Some predicted epidemic scenarios for realistic parameter values yield new COVID-19 infection waves within two years, and high daily case numbers in the endemic state, even without introducing VPs and granting more freedom to their holders. Still, suitable adaptive policies can avoid unfavorable outcomes. While VP holders could initially be allowed more freedom, the lack of full vaccine effectiveness and increased transmissibility will require accelerated (re-)vaccination, wide-spread immunity surveillance, and/or minimal long-term common restrictions.Competing Interest StatementOther projects in the research lab of ES are co-funded by Merck Healthcare KGaAFunding StatementTC has received funding from the European Union s Horizon 2020 research and innovation programme under grant agreement No 101016233 (PERISCOPE) GG acknowledges support by the University of Trento within the COVID-19 Strategic Project MOSES (Models for Reasoning about the Spreading of Diseases). MP was supported by the Slovenian Research Agency (Grant Nos. P1-0403 and J1-2457). EP acknowledges support by the University of Crete. ES acknowledges funding by the Polish National Science Centre OPUS grant no 2019/33/B/NZ2/00956 and SONATA-BIS grant no 2020/38/E/NZ2/00305Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:no IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable https://github.com/storaged/VAP-SIRS https://github.com/eMaerthin/VAP_SIRS_ananysis http://bioputer.mimuw.edu.pl:85/VAP-SIRS/ ER -